Skip to Main Content
Skip Nav Destination

The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series

Inflamm Intest Dis (2017) 2 (2): 131–138.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Carlo Alberto Maronese
  • Matthew A. Pimentel
  • May M. Li
  • Giovanni Genovese
  • Alex G. Ortega-Loayza
  • Angelo Valerio Marzano
American Journal of Clinical Dermatology (2022) 23 (5): 615.
  • Jan Marsal
  • Manuel Barreiro-de Acosta
  • Irina Blumenstein
  • Maria Cappello
  • Thomas Bazin
  • Shaji Sebastian
Frontiers in Medicine (2022) 9
  • Priya Janardhana
  • Saad Al-Kadhi
Current Opinion in Ophthalmology (2021) 32 (6): 549.
  • Paola Conigliaro
  • Maria Sole Chimenti
  • Paola Triggianese
  • Arianna D’Antonio
  • Giorgia Sena
  • Norma Alfieri
  • Livia Biancone
  • Roberto Perricone
Medicine (2021) 100 (12): e25122.
  • Ana Teresa Melo
  • Raquel Campanilho-Marques
  • João Eurico Fonseca
Human Vaccines & Immunotherapeutics (2021) 17 (6): 1586.
  • Tim Raine
  • Bram Verstockt
  • Uri Kopylov
  • Konstantinos Karmiris
  • Rimma Goldberg
  • Raja Atreya
  • Johan Burisch
  • John Burke
  • Pierre Ellul
  • Charlotte Hedin
  • Stefan D Holubar
  • Konstantinos Katsanos
  • Triana Lobaton
  • Carsten Schmidt
  • Garret Cullen
Journal of Crohn's and Colitis (2021) 15 (10): 1605.
  • Caroline Di Jiang
  • Tim Raine
Therapeutic Advances in Musculoskeletal Disease (2020) 12
  • Sebastián Eduardo Ibáñez Vodnizza
  • María Paz Poblete De La Fuente
  • Elisa Catalina Parra Cancino
Rheumatic Disease Clinics of North America (2020) 46 (2): 275.
  • Karma Yeshi
  • Roland Ruscher
  • Luke Hunter
  • Norelle L. Daly
  • Alex Loukas
  • Phurpa Wangchuk
Journal of Clinical Medicine (2020) 9 (5): 1273.
  • Maria Concetta Miceli
  • Chiara Arcuri
  • Sara Renna
  • Ambrogio Orlando
  • Giuseppe Provenzano
Alimentary Pharmacology & Therapeutics (2020) 51 (12): 1449.
Reactions Weekly (2018) 1683 (1): 333.
Close Modal

or Create an Account

Close Modal
Close Modal